Agios Pharmaceuticals Inc. AGIO stock is trading lower after the update on the sickle cell disease program. The company ...

Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a ...

Gene editing has delivered remarkable results against sickle cell disease. Now researchers are working to make these personalized treatments faster, cheaper, and available to far more patients.

Stock drops after development setback Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares fell 14% on Tuesday after the company ...

Researchers from multiple institutions in China have found a way to use gene editing to reactivate dormant fetal oxygen-transporting proteins in adult blood cells to potentially reverse a wide range ...

Saritee Sanodiya, 26, has spent countless days wondering if she’ll ever live a “normal” life. Growing up, Sanodiya often missed school, frequenting the hospital for sudden, life-threatening drops in ...

The first person to ever be cured of sickle cell anemia in Louisiana received revolutionary gene therapy. The treatment is now offered at this hospital.

Agios Pharmaceuticals said tebapivat fell short of expectations in a Phase 2 test in sickle cell disease. It’s the latest in ...

Modern medicine is one step closer to potentially curing sickle cell disease. On the heels of the U.K.'s authorizing the world’s first gene-edited treatment for sickle cell disease on Nov. 16, the U.S ...

Sickle cell disease causes premature aging of blood stem cells, which scientists may be able to address with a special class ...